XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Related Parties
 3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Related Parties

12. Related Parties

The Company was founded out of Dr. Thomas Gajewski’s laboratory at the University of Chicago. In 2020, the Company entered into the License Agreement with the University of Chicago, as well as a sponsored research agreement. During the three months ended March 31, 2023 and 2022, the Company did not incur expenses related to the University License Agreement. Refer to Note 6 for additional discussion.

Pfizer owns more than 10% of the Company and is considered the principal owner of the Company. On October 6, 2022, the Company entered into the A&R License Agreement with Pfizer, which amends and restates the Pfizer License Agreement. During the three months ended March 31, 2023, in accordance with the terms of the A&R License Agreement, the Company paid $8.0 million to Pfizer in January 2023 and issued 1,811,594 shares of its common stock in March 2023. The Company did not incur any expenses related to Pfizer for the three months ended March 31, 2022. Refer to Note 6 for additional discussion.

The Company and Alloy formed a joint venture company, Voxall Therapeutics, LLC (“Voxall”) to leverage the Company’s technology and Alloy’s ATX-Gx™ platform and antibody discovery services. During the three months ended March 31, 2023 and 2022, the Company did not incur expenses related to Voxall. Refer to Note 5 for additional discussion.